All In Biotech

Company · INCY

Incyte

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Incyte Corporation.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

6

6 still marketed

Novel approvals

5

Approvals since 2021

13

Originals and new uses

Phase 3 trials

62

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Zynyz new use OrphanMay 18, 2026
  • Jakafi Xr approved OrphanMay 1, 2026
  • Zynyz new use OrphanMar 30, 2026
  • Zynyz new use OrphanDec 17, 2025
  • Opzelura new use Sep 18, 2025
  • Zynyz new use Priority reviewOrphanMay 15, 2025
  • Niktimvo approved NovelPriority reviewOrphanAug 14, 2024
  • Zynyz approved NovelAccelerated approvalPriority reviewOrphanMar 22, 2023
  • Jakafi new use Priority reviewOrphanDec 19, 2022
  • Pemazyre new use Breakthrough therapyPriority reviewOrphanAug 26, 2022

Drugs in development (11)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (6)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.